A research team from the Cleveland Clinic has released a groundbreaking study examining the independent effects of weight loss and blood sugar management on clinical outcomes in individuals with type 2 diabetes. This research specifically focuses on patients treated with GLP-1 receptor agonists (GLP-1RAs), including popular medications like Ozempic and Wegovy.
The study revealed significant findings: for every 1% reduction in body mass index (BMI), there was a corresponding 4% decrease in cardiovascular risk, independent of changes in blood sugar levels. Additionally, improved blood sugar control—regardless of weight loss—was associated with a reduced risk of developing chronic kidney disease. These results underscore the critical need for a dual approach in treating type 2 diabetes that addresses both glycemic control and obesity.
The retrospective study analyzed deidentified electronic health records of over 1,300 patients with type 2 diabetes at the Cleveland Clinic, and its findings were published in the journal Diabetes, Obesity and Metabolism. The results highlight the clinical significance of managing both weight and blood sugar to enhance health outcomes for individuals living with this condition.
